Biomarkers of endothelial activation/dysfunction distinguish sub-groups of Ugandan patients with sepsis and differing mortality risks.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
23 04 2019
Historique:
entrez: 24 4 2019
pubmed: 24 4 2019
medline: 21 10 2020
Statut: epublish

Résumé

Sepsis is a complex clinical syndrome with substantial heterogeneity. We sought to identify patterns of serum biomarkers of endothelial activation and dysfunction in individuals with sepsis and evaluate subgroup-specific differences in mortality. Adult patients with sepsis (n=426) were consecutively recruited from two hospitals in Uganda. Clinical information was collected and serum concentrations of eleven biomarkers involved in the endothelial response to infection were measured in samples from 315 patients. Latent variable models were fit to evaluate whether the endothelial response to sepsis consists of one unified biological process or multiple processes and to identify subgroups of patients with distinct host-response profiles. Differences in survival at day 28 were evaluated using Kaplan-Meier survival curves. We identified three patient subgroups characterized by unique host endothelial response profiles. Patients fitting Profile 2 had significantly worse survival (log-rank p<0.001). Four latent factors (Factor 1-4) were identified, each potentially representing distinct biological processes for the endothelial response to sepsis: Factor 1 (CHI3L1, sTREM1, sFLT1); Factor 2 (ANGPT1, PF4, VEGF); Factor 3 (CXCL10, VWF, sICAM1); and Factor 4 (ANGPT2, sTEK). Patient profiles based on patterns of circulating biomarkers of endothelial responses may provide a clinically meaningful way to categorize patients into homogeneous subgroups and may identify patients with a high risk of mortality. Profile 2 may represent dysfunction of the endothelial response to infection. Primary funding: Investigator-Initiated Award provided by Pfizer, Inc (WMS, STJ). Additional support: Canadian Institutes of Health Research (CIHR) Foundation grant (KCK; FDN-148439) and the Canada Research Chair program (KCK).

Sections du résumé

BACKGROUND
Sepsis is a complex clinical syndrome with substantial heterogeneity. We sought to identify patterns of serum biomarkers of endothelial activation and dysfunction in individuals with sepsis and evaluate subgroup-specific differences in mortality.
METHODS
Adult patients with sepsis (n=426) were consecutively recruited from two hospitals in Uganda. Clinical information was collected and serum concentrations of eleven biomarkers involved in the endothelial response to infection were measured in samples from 315 patients. Latent variable models were fit to evaluate whether the endothelial response to sepsis consists of one unified biological process or multiple processes and to identify subgroups of patients with distinct host-response profiles. Differences in survival at day 28 were evaluated using Kaplan-Meier survival curves.
RESULTS
We identified three patient subgroups characterized by unique host endothelial response profiles. Patients fitting Profile 2 had significantly worse survival (log-rank p<0.001). Four latent factors (Factor 1-4) were identified, each potentially representing distinct biological processes for the endothelial response to sepsis: Factor 1 (CHI3L1, sTREM1, sFLT1); Factor 2 (ANGPT1, PF4, VEGF); Factor 3 (CXCL10, VWF, sICAM1); and Factor 4 (ANGPT2, sTEK).
CONCLUSION
Patient profiles based on patterns of circulating biomarkers of endothelial responses may provide a clinically meaningful way to categorize patients into homogeneous subgroups and may identify patients with a high risk of mortality. Profile 2 may represent dysfunction of the endothelial response to infection.
FUNDING
Primary funding: Investigator-Initiated Award provided by Pfizer, Inc (WMS, STJ). Additional support: Canadian Institutes of Health Research (CIHR) Foundation grant (KCK; FDN-148439) and the Canada Research Chair program (KCK).

Identifiants

pubmed: 31013257
pii: 127623
doi: 10.1172/jci.insight.127623
pmc: PMC6542598
doi:
pii:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : FDN-148439
Pays : Canada

Références

Infect Dis Clin North Am. 1999 Jun;13(2):285-97, vii
pubmed: 10340167
Crit Care Med. 1999 Aug;27(8):1608-16
pubmed: 10470773
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1120-2
pubmed: 10988140
Immunology. 2001 Sep;104(1):99-108
pubmed: 11576227
Nat Rev Immunol. 2003 Jun;3(6):445-53
pubmed: 12776204
Psychometrika. 1965 Jun;30:179-85
pubmed: 14306381
Chest. 2004 Jun;125(6):2156-9
pubmed: 15189936
J Infect. 2006 Apr;52(4):264-8
pubmed: 16102836
PLoS Med. 2006 Mar;3(3):e46
pubmed: 16417407
Trends Immunol. 2006 Dec;27(12):552-8
pubmed: 17045842
Dev Cell. 2008 Jan;14(1):25-36
pubmed: 18194650
Crit Care Med. 2008 Mar;36(3):964-6
pubmed: 18431286
J Exp Med. 2008 Sep 1;205(9):2065-74
pubmed: 18695007
PLoS Med. 2008 Aug 19;5(8):e175
pubmed: 18752342
Mol Immunol. 2009 Dec;47(2-3):485-92
pubmed: 19767105
Crit Care. 2010;14(1):R15
pubmed: 20144219
J Med Assoc Thai. 2010 Jan;93 Suppl 1:S102-9
pubmed: 20364564
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
J Biol Chem. 2011 Apr 29;286(17):15332-43
pubmed: 21385870
Eur J Clin Microbiol Infect Dis. 2012 Jan;31(1):73-6
pubmed: 21559767
Sci Transl Med. 2011 Jun 22;3(88):88ps25
pubmed: 21697528
Ann Intensive Care. 2011 Jul 19;1(1):27
pubmed: 21906380
Am J Respir Crit Care Med. 2012 Mar 15;185(6):628-36
pubmed: 22246174
Crit Care Med. 2012 Jul;40(7):2050-8
pubmed: 22564958
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
PLoS One. 2013 Aug 05;8(8):e70305
pubmed: 23940557
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Virulence. 2014 Jan 1;5(1):4-11
pubmed: 24335434
J Infect. 2014 May;68(5):440-7
pubmed: 24393650
Med Image Comput Comput Assist Interv. 2014;17(Pt 2):138-45
pubmed: 25485372
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Virulence. 2016 May 18;7(4):387-94
pubmed: 26818467
Multivariate Behav Res. 1966 Apr 1;1(2):245-76
pubmed: 26828106
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2017 Mar;45(3):486-552
pubmed: 28098591
PLoS One. 2017 Apr 18;12(4):e0175130
pubmed: 28419100
Eur Respir J. 1995 Aug;8(8):1352-6
pubmed: 7489803
Clin Exp Immunol. 1993 Dec;94(3):522-6
pubmed: 7504602
Crit Care Med. 1998 Jun;26(6):1020-4
pubmed: 9635649
Eur Respir J. 1998 Dec;12(6):1375-9
pubmed: 9877494

Auteurs

Danielle V Clark (DV)

Austere environments Consortium for Enhanced Sepsis Outcomes, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.

Patrick Banura (P)

Ministry of Health, Uganda; Kampala, Uganda.

Karen Bandeen-Roche (K)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

W Conrad Liles (WC)

Departments of Medicine, Pathology, Pharmacology, and Global Health, University of Washington, Seattle, Washington, USA.

Kevin C Kain (KC)

Tropical Disease Unit, University Health Network-Toronto General Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

W Michael Scheld (WM)

Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.

William J Moss (WJ)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Shevin T Jacob (ST)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH